Novo Nordisk Raises 2026 Profit Guidance Amid Strong Wegovy Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: CNBC
- Sales Surge: Novo Nordisk reported a 32% year-on-year increase in first-quarter sales to 96.8 billion Danish kroner ($15.2 billion), significantly exceeding analyst expectations of 71.3 billion kroner, indicating robust demand for its weight-loss drugs and reinforcing its leadership in the obesity treatment market.
- Profit Boost: Operating profit soared 65% year-on-year to 59.6 billion kroner, greatly surpassing market expectations of 31.7 billion kroner, reflecting successful strategies in cost control and market expansion, which bolstered investor confidence.
- New Drug Highlights: The oral weight-loss drug Wegovy generated sales of 2.26 billion kroner in the U.S., well above analyst estimates of 1.16 billion kroner, marking a strong market entry that could reshape competitive dynamics in the weight-loss sector.
- Optimistic Market Outlook: The company raised its 2026 full-year profit guidance based on increased expectations for GLP-1 product sales, now forecasting adjusted sales to contract by 4% to 12%, demonstrating confidence in future market demand despite intense competitive pressures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 45.800
Low
42.00
Averages
54.67
High
70.00
Current: 45.800
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's GLP-1 Sales Surge in India Following Price Cuts
- Significant Sales Growth: Novo Nordisk's GLP-1 drug semaglutide saw a 40% sales increase in India last month, reaching 32,000 units, demonstrating the effectiveness of its price-cutting strategy despite generic competition.
- Price Strategy Adjustment: The company reduced the starting doses of Wegovy and Ozempic by 36% and 48% to ₹5,660 (approximately $60) to counter the impact of local low-cost generics, thereby enhancing its market competitiveness.
- Market Expansion Trend: The GLP-1 market in India expanded to 414,000 units in April, a 56% increase from the previous month, reflecting strong demand for low-priced generics, while Eli Lilly maintains its leadership position.
- Patent Expiry Impact: With Novo Nordisk losing exclusivity for semaglutide's core patent in India, the company projects a potential profit decline of 5%-13% in the future, posing challenges for its strategic positioning in global markets.
See More
On-Demand Access to Precious Metals & Critical Minerals Virtual Investor Conference Presentations
- Conference Content Replay: Presentations from the Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing, allowing investors, advisors, and analysts to access content 24/7 for 90 days, thereby enhancing convenience and flexibility in information retrieval.
- One-on-One Meeting Arrangements: Selected companies are accepting requests for one-on-one management meetings, enabling investors to communicate directly with company leadership, which enhances interaction and transparency between investors and companies.
- Resource Download Convenience: Attendees can download investor materials from the company's resource section, which not only provides comprehensive information support for investors but also promotes a deeper understanding of the company's business.
- Advantages of Virtual Conferences: Virtual Investor Conferences offer real-time investor engagement solutions that improve the efficiency of connections between companies and investors, marking a new trend in investor relations management, especially among retail and institutional investors globally.
See More
Labour Party Faces Heavy Losses in Local Elections
- Election Setbacks: The Labour Party is experiencing significant losses in local elections, losing key seats and facing pressure from right-wing parties like Reform UK, indicating a decline in voter confidence that could lead to leadership challenges.
- Rising Borrowing Costs: U.K. borrowing costs have reached their highest level since 1998 ahead of the elections, intensifying market pressures on political challenges and potentially impacting future economic policies and investment confidence.
- Calls for Leadership Change: There are growing calls within the Labour Party for a leadership change, with former Shadow Chancellor John McDonnell stating that leadership transition must be on the agenda, reflecting internal dissatisfaction and concerns about the party's future direction.
- International Tensions: The U.S. and Iran have exchanged fire in the Strait of Hormuz, with both sides blaming each other, which could complicate the upcoming meeting between Trump and Xi, further exacerbating global market uncertainties.
See More
First Generic Versions of Ozempic Approved in Canada
- Generic Approval: Health Canada approved the first generic versions of Ozempic from Dr. Reddy's Laboratories on April 28, followed by another from Apotex, marking the beginning of increased market competition.
- Market Impact Assessment: Analyst Evan Seigerman noted that these new generics could lead to a decline in international revenue for semaglutide, although the impact on the U.S. market is expected to be limited due to competition from Eli Lilly's Mounjaro.
- Novo's Response Strategy: Emil Kongshøj Larsen, EVP of International Operations at Novo Nordisk, stated that the impact of generics is anticipated to be in the low single digits, highlighting the strong uptake of their savings card strategy in Canada.
- Pricing Policy Change: Canadian policy mandates a 65% price cut to Novo's list price once three generic competitors enter the market, which will significantly influence their future market strategy.
See More
Eli Lilly's Stock Surge and Competitor Analysis
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 weight loss drugs saw sales increase by 125% and 80% in Q1 2026, showcasing robust performance in a rapidly evolving pharmaceutical market, although its P/E ratio stands at 34x, above the industry average of 23x, indicating optimistic market expectations for future growth.
- Novo Nordisk Catching Up: Novo Nordisk's newly launched GLP-1 pill gained traction with 1.3 million prescriptions in the first quarter, suggesting a competitive edge in weight loss effectiveness, prompting the company to raise its full-year 2026 guidance and boosting market confidence.
- Pfizer's Challenges: Pfizer has yet to establish a foothold in the GLP-1 market after having to drop its drug candidate; however, it is actively acquiring promising candidates and advancing oncology and migraine drug development, maintaining its long-standing industry leadership.
- Market Sentiment Analysis: Wall Street's enthusiasm for Eli Lilly has inflated its valuation, prompting caution among long-term investors, while the undervaluation of Novo Nordisk and Pfizer may present greater upside potential, especially in light of overly pessimistic market sentiment.
See More
McDonald's Q1 Earnings Exceed Expectations
- McDonald's Strong Performance: McDonald's reported a 3.8% increase in global comparable sales for Q1, surpassing the 3.7% consensus estimate, driven by the introduction of the high-margin Big Arch burger and value offerings, thereby enhancing its competitive position in the fast-food market.
- Novo Nordisk Drug Launch: Novo Nordisk's oral diabetes medication Ozempic is now available for same-day delivery through Amazon's pharmacy, leading to a 0.83% stock increase, marking a significant advancement in digital distribution channels that could enhance its market share.
- Datadog Earnings Surge: Datadog's Q1 non-GAAP EPS jumped approximately 30% year-over-year to $0.60, with revenue climbing around 32% to about $1 billion, exceeding analyst expectations and resulting in a roughly 20% premarket stock surge, indicating strong market demand and positive company outlook.
- Papa John's Sales Decline: Papa John's reported a 7.7% drop in total revenue to $478.6 million in Q1, with North American comparable sales down 6.4%, despite a 3.6% growth in international operations, highlighting challenges the company faces in a competitive market.
See More
Novo Nordisk's GLP-1 Sales Surge in India Following Price Cuts
- Significant Sales Growth: Novo Nordisk's GLP-1 drug semaglutide saw a 40% sales increase in India last month, reaching 32,000 units, demonstrating the effectiveness of its price-cutting strategy despite generic competition.
- Price Strategy Adjustment: The company reduced the starting doses of Wegovy and Ozempic by 36% and 48% to ₹5,660 (approximately $60) to counter the impact of local low-cost generics, thereby enhancing its market competitiveness.
- Market Expansion Trend: The GLP-1 market in India expanded to 414,000 units in April, a 56% increase from the previous month, reflecting strong demand for low-priced generics, while Eli Lilly maintains its leadership position.
- Patent Expiry Impact: With Novo Nordisk losing exclusivity for semaglutide's core patent in India, the company projects a potential profit decline of 5%-13% in the future, posing challenges for its strategic positioning in global markets.
See More
On-Demand Access to Precious Metals & Critical Minerals Virtual Investor Conference Presentations
- Conference Content Replay: Presentations from the Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing, allowing investors, advisors, and analysts to access content 24/7 for 90 days, thereby enhancing convenience and flexibility in information retrieval.
- One-on-One Meeting Arrangements: Selected companies are accepting requests for one-on-one management meetings, enabling investors to communicate directly with company leadership, which enhances interaction and transparency between investors and companies.
- Resource Download Convenience: Attendees can download investor materials from the company's resource section, which not only provides comprehensive information support for investors but also promotes a deeper understanding of the company's business.
- Advantages of Virtual Conferences: Virtual Investor Conferences offer real-time investor engagement solutions that improve the efficiency of connections between companies and investors, marking a new trend in investor relations management, especially among retail and institutional investors globally.
See More
Labour Party Faces Heavy Losses in Local Elections
- Election Setbacks: The Labour Party is experiencing significant losses in local elections, losing key seats and facing pressure from right-wing parties like Reform UK, indicating a decline in voter confidence that could lead to leadership challenges.
- Rising Borrowing Costs: U.K. borrowing costs have reached their highest level since 1998 ahead of the elections, intensifying market pressures on political challenges and potentially impacting future economic policies and investment confidence.
- Calls for Leadership Change: There are growing calls within the Labour Party for a leadership change, with former Shadow Chancellor John McDonnell stating that leadership transition must be on the agenda, reflecting internal dissatisfaction and concerns about the party's future direction.
- International Tensions: The U.S. and Iran have exchanged fire in the Strait of Hormuz, with both sides blaming each other, which could complicate the upcoming meeting between Trump and Xi, further exacerbating global market uncertainties.
See More
First Generic Versions of Ozempic Approved in Canada
- Generic Approval: Health Canada approved the first generic versions of Ozempic from Dr. Reddy's Laboratories on April 28, followed by another from Apotex, marking the beginning of increased market competition.
- Market Impact Assessment: Analyst Evan Seigerman noted that these new generics could lead to a decline in international revenue for semaglutide, although the impact on the U.S. market is expected to be limited due to competition from Eli Lilly's Mounjaro.
- Novo's Response Strategy: Emil Kongshøj Larsen, EVP of International Operations at Novo Nordisk, stated that the impact of generics is anticipated to be in the low single digits, highlighting the strong uptake of their savings card strategy in Canada.
- Pricing Policy Change: Canadian policy mandates a 65% price cut to Novo's list price once three generic competitors enter the market, which will significantly influence their future market strategy.
See More
Eli Lilly's Stock Surge and Competitor Analysis
- Eli Lilly's Strong Performance: Eli Lilly's GLP-1 weight loss drugs saw sales increase by 125% and 80% in Q1 2026, showcasing robust performance in a rapidly evolving pharmaceutical market, although its P/E ratio stands at 34x, above the industry average of 23x, indicating optimistic market expectations for future growth.
- Novo Nordisk Catching Up: Novo Nordisk's newly launched GLP-1 pill gained traction with 1.3 million prescriptions in the first quarter, suggesting a competitive edge in weight loss effectiveness, prompting the company to raise its full-year 2026 guidance and boosting market confidence.
- Pfizer's Challenges: Pfizer has yet to establish a foothold in the GLP-1 market after having to drop its drug candidate; however, it is actively acquiring promising candidates and advancing oncology and migraine drug development, maintaining its long-standing industry leadership.
- Market Sentiment Analysis: Wall Street's enthusiasm for Eli Lilly has inflated its valuation, prompting caution among long-term investors, while the undervaluation of Novo Nordisk and Pfizer may present greater upside potential, especially in light of overly pessimistic market sentiment.
See More
McDonald's Q1 Earnings Exceed Expectations
- McDonald's Strong Performance: McDonald's reported a 3.8% increase in global comparable sales for Q1, surpassing the 3.7% consensus estimate, driven by the introduction of the high-margin Big Arch burger and value offerings, thereby enhancing its competitive position in the fast-food market.
- Novo Nordisk Drug Launch: Novo Nordisk's oral diabetes medication Ozempic is now available for same-day delivery through Amazon's pharmacy, leading to a 0.83% stock increase, marking a significant advancement in digital distribution channels that could enhance its market share.
- Datadog Earnings Surge: Datadog's Q1 non-GAAP EPS jumped approximately 30% year-over-year to $0.60, with revenue climbing around 32% to about $1 billion, exceeding analyst expectations and resulting in a roughly 20% premarket stock surge, indicating strong market demand and positive company outlook.
- Papa John's Sales Decline: Papa John's reported a 7.7% drop in total revenue to $478.6 million in Q1, with North American comparable sales down 6.4%, despite a 3.6% growth in international operations, highlighting challenges the company faces in a competitive market.
See More
